Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine in Bariatric Surgery
NCT03276026Phase 4Terminated
- Sponsor
- Virtua Health
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Virtua Health. Primary endpoint: Post Anesthesia Care Unit Length of Stay at 120 minutes. Started Feb 2018; status: terminated.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03276026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276026.